NCT07424157

Long-Term Follow-Up of Subjects Treated With Seattle Children's Therapeutics Gene Therapy Products

• Status: Not Yet Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 500 (estimated)
• Sponsor: Seattle Children's Hospital · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

Subjects exposed to gene therapy products (GTPs) may be at risk for delayed or long-term adverse events. This is a long-term follow-up (LTFU) protocol designed to evaluate the long-term safety of Seattle Children's Therapeutics (SCTx) GTPs and incorporates in monitoring guidance from the U.S. Food and Drug Administration (FDA). Subjects will be followed for up to 15 years starting from the date of the most recent infusion of an SCTx GTP. Subjects planning to receive, or who have received, at least one infusion of an SCTx GTP will be offered participation in this LTFU study. Subjects enrolled in this study will have safety assessments and laboratory evaluations performed at scheduled intervals for each unique SCTx GTP received. No treatment is administered in this LTFU study.

Conditions

• CAR T Cell
• CAR T Cell Therapy

Interventions

Type	Name	Description
OTHER	Long term follow up in all patients who received an SCTx gene therapy product	Participants will be followed for 15 years following the receipt of their final infusion on a separate SCTx gene therapy protocol to monitor for the long term effects of CAR T cell therapy

Timeline

• Start date: 2026-03-31
• Primary completion: 2041-03-31
• Completion: 2041-03-31
• First posted: 2026-02-20
• Last updated: 2026-02-20

Locations

1 site across 1 country: United States